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Abstract
In early phase dose-finding cancer studies, the objective is to determine the maximum tolerated
dose, defined as the highest dose with an acceptable dose-limiting toxicity rate. Finding this dose
for drug-combination trials is complicated due to drug-drug interactions, and many trial designs
have been proposed to address this issue. These designs rely on complicated statistical models that
typically are not familiar to clinicians, and are rarely used in practice. The aim of this paper is
to propose a Bayesian dose-finding design for drug combination trials based on standard logistic
regression. Under the proposed design, we continuously update the posterior estimates of the model
parameters to make the decisions of dose assignment and early stopping. Simulation studies show
that the proposed design is competitive and outperforms some existing designs. We also extend our
design to handle delayed toxicities.
Keywords: Bayesian inference; Dose-finding; Drug combination; Oncology; Phase I trial.
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1 Introduction
For oncologists, the objective of phase I dose-finding studies is to determine the maximum tolerated
dose (MTD), defined as the highest dose with a relatively acceptable dose-limiting toxicity (DLT)
[1, 2]. DLT is usually defined as a toxicity of grade 3 or higher according to the U.S. National
Cancer Institute toxicity criteria [3]. In practice, patients included in phase I clinical cancer trials
have already been heavily pre-treated and in many cases no alternative therapeutic options are
available to them. For cytotoxic anti-cancer drugs, a dose-toxicity effect is assumed whereby the
higher the dose, the greater the risk of DLT and the greater the efficacy.
Dose finding for drug combination trials is more difficult than that for conventional single-
agent trials due to complicated drug-drug interactions. Moreover, when combining several agents,
the order of the toxicity probabilities is not fully known. Should investigators wish to gradually
increase the acceptable level of toxicity during the trial, the appropriate order in which the doses for
the various drugs in the combination should be increased would be of great interest. For instance,
when combining two cytotoxic agents, it remains difficult to decide how to escalate or de-escalate
the dose combination, even when a partial ordering is known [4, 5].
Recently, many phase I dose-finding designs have been proposed for drug combination trials.
Thall et al. proposed a Bayesian dose-finding method based on a six-parameter model [6]. Wang
and Ivanova developed a 3-parameter model-based method in which the parameters are estimated
using Bayesian inference [7]. Mandrekar et al. proposed an approach incorporating the toxicity and
efficacy of each agent into the identification of an optimal dosing region for the combination by us-
ing a continuation ratio model to separate each agent’s toxicity and efficacy curves [8, 9]. Yin and
Yuan developed a Bayesian adaptive design based on latent 2x2 tables in which the combination’s
toxicity probabilities in the two-dimensional space are estimated using a Gumbel-type model [10].
Yin and Yuan extended their method by changing to a copula-type model to simulate the effect of
two or more drugs in combination [11]. Bailey et al. introduced a second agent as a covariate in
a logistic model [12]. Wages et al. considered an approach based on the continual reassessment
method and taking into account different orderings with partial order between combinations. In this
case, the MTD is estimated for the order associated with the highest model-selection criterion [5].
Most of these existing designs rely on complicated statistical models that typically are not familiar
to clinicians, which hinder their acceptance and application in practice. In addition, the perfor-
mance of these designs seems comparable and there is no consensus which design should be used
[13]. As a result, many of the dose-finding clinical trials conducted to evaluate drug combinations
still use the conventional “3+3” approach, which was developed for single agents and was shown
to be inefficient in terms of dose identification [14, 15, 16, 17, 18].
In this paper, we propose an Bayesian dose-finding design for drug combination trials based
on standard logistic regression. Under the Bayesian paradigm, data monitoring, early stopping
and dose assignment occur continuously throughout the trial by updating the posterior estimates of
the model parameters. Simulation studies show that in general the proposed design provide better
performance than some existing designs. To facilitate the use of the proposed design by clinicians,
R package will be developed for implementing the new design.
This manuscript is laid out as follows: in Section 2, we propose the simple statistical method
for modeling the toxicity probabilities of the drug combination under evaluation. Moreover, we
present the likelihood function and the prior specifications for the unknown parameters. In this
section, we also describe our allocation and dose-finding method, as well as propose stopping rules.
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We conduct extensive simulation studies to examine the operating characteristics of our design in
Sections 3 and 4, and conclude with a discussion in Section 5.
2 Methods
2.1 Statistical method for combination evaluation (LOGISTIC)
Dose-combination model
Let there be a two-drug combination used in a phase I dose-finding clinical trial for which the
dose-toxicity relationship is monotonic and increases with the dose levels. Let (j; k) denote the
dose level of a combination in which j refers to Agent 1 (j = 1; : : : ; J), and k refers to Agent 2
(k = 1; : : : ; K). Yi is a Bernoulli random variable, denoting the toxicity that is equal to 1 if DLT
occurs in patient i and 0 otherwise (i = 1; : : : ; N). We assume that nj;k patients are allocated at
combination (j; k) and that a total of tj;k DLTs are observed for that combination. We define j;k as
the toxicity probabilities of combination (j; k),  as the target probability of toxicity, and p1, ..., pJ
and q1, ..., qK as the respective prior toxicity probabilities of Agent 1 and Agent 2 taken alone. For
simplicity purposes, we refer to the selected combination as the MTD in order to maintain the same
designation as in single-agent trials. In this manuscript, we focus on finding one MTD at the end
of the trial. We note that in some cases, it is of interest to find multiple MTDs that can be further
tested in phase II trials, see Yuan and Yin [19] and Ivanova and Wang [20] for related designs.
Let uj and vk denote the “effective” or standardized doses ascribed to the jth level of Agent 1
and k level of Agent 2, respectively. We model the drug combination-toxicity relationship using a
4-parameter logistic model, as follows:
logit(j;k) = 0 + 1uj + 2vk + 3ujvk; (1)
where 0, 1, 2 and 3 are unknown parameters that represent the toxicity effect of Agent 1 (1),
that of Agent 2 (2) and that of the interaction between the two agents (3). These parameters are
defined such that 1 > 0 and 2 > 0, ensuring that the toxicity probability is increasing with the
increasing dose level of each agent alone, 8k; 1 + 3vk > 0 and 8j; 2 + 3uj > 0, ensuring that
the toxicity probability is increasing with the increasing dose levels of both agents together, and
intercept  1 < 0 < 1. The standardized dose of two agents are defined as uj = log

pj
1 pj

and vk = log

qk
1 qk

, where pj and qk are the prior estimates of the toxicity probabilities of the jth
dose level of Agent 1 and the kth dose level of Agent 2, respectively, when they are administered
individually as a single agent. Before two agents can be combined, each of them typically have
been thoroughly investigated individually. Therefore, there is often rich prior information on pj’s
and qk’s and their values can be readily elicited from physicians. Using the prior information to
define standardized dose has been widely used in dose-finding trial designs, and the most well
known example perhaps is the skeleton of the continuous reassessment method (CRM) [21] with a
logistic model. Research has shown that this approach improves the estimation stability and trial
performance [2, 22]. Our definition of uj and vk can be viewed as an extension of the skeleton of
the CRM (with a logistic model) to drug-combination trials.
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Likelihood and posterior inference
Under the proposed model, the likelihood is simply a product of the Bernoulli density, given by
L(0; 1; 2; 3jdata) /
JY
j=1
KY
k=1

tj;k
j;k (1  j;k)nj;k tj;k :
We assume the prior distributions of the model parameters are independent. For 0 and 3, we
assign a vague normal prior N(0; 10) centered at 0 to indicate that a priori we do not favor either
positive or negative values for these parameters and let the observed data speak for themselves
through posteriors. For 1 and 2, we assume an informative prior distribution Exp(1) centered
at 1, as those parameters should not be too far from 1. Then, the joint posterior distribution of
parameters 0; 1; 2 and 3 is given by
f(0; 1; 2; 3jdata) / L(0; 1; 2; 3jdata)f(0)f(1)f(2)f(3): (2)
We sample this posterior distribution using Gibbs sampler, which sequentially draws each of the
parameters from their full conditional distributions (see Appendix). These full conditional dis-
tributions do not have closed forms, and we use the Adaptive Rejection Metropolis Sampling
(ARMS) method [23] to sample them. In order to impose the constrain that 8k; 1 + 3vk > 0
and 8j; 2 + 3uj > 0, at each iteration of Gibbs sampling, if sampled 1, 2 and 3 fail to satisfy
the constraint, we re-sample 1, 2 and 3. Let (
(`)
0 ; 
(`)
1 ; 
(`)
2 ; 
(`)
3 )`=1;:::;L denote the L posterior
samples obtained from Gibbs sampler, the posterior toxicity probabilities can be estimated using
Monte Carlo by:
~j;k =
1
L
LX
`=1
exp(
(`)
0 + 
(`)
1 uj + 
(`)
2 vk + 
(`)
3 uj vk)
1 + exp(
(`)
0 + 
(`)
1 uj + 
(`)
2 vk + 
(`)
3 uj vk)
:
Dose finding algorithm and determination of the MTD
During the trial conduct, we use the dose-finding algorithm proposed by Yin and Yuan [11, 10] to
determine dose escalation and deescaltion, and propose a different criterion for MTD selection at
the end of the trial. In our design, similar to Yin and Yuan [11], we restrict dose escalation and de-
escalation one level at a time (i.e, we do not allow dose escalate or de-escalate along the diagonal)
based on the practical consideration that physicians are conservative and typically do not allow
two agent to escalate at the same time for patient safety. Nevertheless, we note that Sweeting and
Mander [24] showed that diagonal escalation strategy may be more efficient in reaching the target
toxicity level quicker with fewer patients treated at sub-optimal doses and have a higher percentage
of correct selection at the end of the trial. We take this strategy in our start-up phase described later.
Let ce be the probability threshold for dose escalation and cd the probability threshold for dose
de-escalation. We require ce+cd > 1 to avoid that the decisions of dose escalation and deescalation
occur at the same time. Our dose-finding algorithm can be described as follows:
 If the current combination is (j; k) and P (j;k < jdata) > ce,
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we escalate the combination dose level to an adjacent combination dose level f(j + 1; k),
(j; k+1), (j +1; k  1), (j   1; k+1)g that has a toxicity probability that is higher than the
current value and closest to . If the current combination is the highest of the combination
space, (J;K), we retain the same combination dose level for the next cohort.
 If the current dose combination is (j; k) and P (j;k > jdata) > cd,
we de-escalate the combination dose level to an adjacent combination dose level f(j   1; k),
(j; k   1), (j + 1; k   1), (j   1; k + 1)g that has a toxicity probability that is lower than
the current value and closest to . If the current combination is the lowest of the combination
space, (1; 1), we retain the same combination dose level for the next cohort.
 If the current combination is (j; k) and P (j;k < jdata)  ce and P (j;k > jdata)  cd,
we treat the next cohort of patients at the current combination dose level.
Once we reach the maximum sample size, we select the MTD as the combination associated
with the highest posterior probability, P (j;k 2 [   ;  + ]), and have been used to treat at least
one cohort of patients. If, for example, the target toxicity  is 0:3, and the length around the targeted
interval is  = 0:1, which gives a targeted interval defined as [0:2; 0:4], then, as illustrated in Figure
5, at the end of the trial we can obtain the posterior densities of the toxicity probability for each
combination. Shown in light gray in the figure is the area under the curve (AUC) for a toxicity
probability lower than 0:2, which is equal to the probability of under-dosing. Shown in medium
gray is the AUC for a toxicity probability between 0:2 and 0:4, which is the probability of being
in the targeted interval. Shown in dark gray is the AUC for a toxicity probability greater than 0:4,
which is equal to the probability of overdosing. For each combination, given the probabilities of
being in the targeted interval, the combination already administered to at least one cohort at the end
of the trial and corresponding to the highest probability is selected as the MTD. For example, dose
combination (2; 3), as illustrated in Figure 2.
The probability thresholds ce and cd are critical for the performance of the design as they control
the dose escalation and deescalation. The values of ce and cd should be carefully calibrated through
simulation to ensure good operating characteristics of the design. In practice, this can be done as
follows: first define a set of representative dose-toxicity scenarios that may be encountered in the
trial, and then conduct simulation under different values of ce and cd to evaluate the performance
of the design. This is a trial-and-error process and may involve repeatedly tuning the values of
ce and cd based on the simulation results. The goal is to find the values of ce and cd that yield
good overall performance across different scenarios (e.g., the percentage of correct selection of the
MTD, the number of patients exposed to over-toxic combinations or under-toxic combinations).
Such a calibration based approach has been widely used in clinical trial designs [25, 6, 11, 10].
Due to the limited availability of information at the beginning of the trial, the posterior estimates
of the toxicity probabilities may not be reliable. Therefore, as suggested by other authors [10, 16,
26, 27, 20], we implement an algorithm-based start-up phase in order to gather enough information
to estimate the j;k. Our start-up phase shares the spirit of accelerated titration design [28] and can
be described as follows: treat the first cohort of patients at the lowest dose combination (1; 1); if
no toxicity is observed, escalate the dose along the diagonal and treat the second cohort of patients
at (2; 2); we continue this dose escalation along the diagonal until the observation of a toxicity or
at least one agent is at its maximum. If one of the agents is already at its maximum dose level and
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still no toxicity is observed, we increase the dose of the other agent until both agents reach their
maximum dose level. At any time of the start-phase, once the first toxicity event is observed, the
start-up phase is completed and the design switches to the model-based dose-finding algorithm as
described above.
Stopping rules
Our aim is to propose a design that, should the investigators wish, will stop the trial when all
combinations are estimated to be unacceptable in terms of toxicity. If the current combination is
(1; 1), at least two cohorts have been included and P (j;k < )  0:975, then the trial is stopped.
2.2 Some existing designs for combination studies
BCOPULA and BGUMBEL methods
Yin and Yuan proposed two Bayesian methods that use copula regression for combinations. The
first method [11] uses a Clayton-copula regression in order to express the joint probability of com-
bination (j; k) with the marginal true probabilities of toxicity (pj ; q

k ) :
j;k = 1 

(1  pj )  + (1  qk )    1
  1

:
The second design [10] uses a Gumbel model:
j;k = 1  (1  pj )(1  qk )

1 + pj q

k
e   1
e + 1

;
where ; ;  > 0 are unknown parameters. The parameter  characterizes the drug interactive
effect, and  and  the uncertainty of the initial guesses. The combination allocation algorithm
is the same as that presented in Section 2.1. The final MTD is the combination with a toxicity
probability closest to the target among the combinations already administered in the trial.
I2D method
Wang and Ivanova proposed the I2D method [7], which is a two-dimensional model-based design,
defined as follows [7]:
j;k = 1  (1  pj)(1  qk) exp (  log(1  pj) log(1  qk)) ;
where  > 0,  > 0, the interaction term  > 0, and pj , qk are the working models for Agent 1 and
Agent 2, respectively.
The combination that will be allocated to the next cohort is the combination closest to the target
that belongs to f(j + 1; k), (j; k + 1), (j   1; k + 1), (j   1; k), (j; k   1), (j + 1; k   1), (j; k)g.
The final MTD is defined as the combination with a toxicity probability closest to the target among
the combinations already administered in the trial.
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LOGODDS
Gasparini, Bailey and Neuenschwander [29] have proposed an alternative model, j;k, to the copula
proposed by Yin and Yuan [11] containing an interaction parameter  which explicitly quantifies
departure from no interaction on the log-odds scale:
 = logodds(j;k)  logodds(?j;k)
where ?j;k is the no-interaction model defined as 
?
j;k = pj + qk   pjqk. By backsolving
this equation, an explicit expression for the probability of toxicity is obtained. A normal prior
centered in 0 and with variance of 100 was chosen for the interaction parameter. The rest of the
dose allocation process, estimation and MTD determination was the same as our proposed design
in order to compare our method involving a simple interaction logistic model with other logistic
models.
TMML
Thall et al. [6] proposed a six-parameter model defined as follows:
j;k =
1x
1
1 + 2x
2
2 + 3(x
1
1 x
2
2 )
3
1 + 1x
1
1 + 2x
2
2 + 3(x
1
1 x
2
2 )
3
where 1; 1; 2; 2; 3; 3 are unknown positive parameters. Following Thall [6], a prior
gamma distribution with parameters (0:3; 0:3) was chosen for 1, 2 and 3, and a gamma dis-
tribution with parameters (0:003; 0:03) was chosen for 1, 2 and 3. The rest of the dose alloca-
tion process, estimation and MTD determination was the same as our proposed design in order to
compare our method involving a simple interaction logistic model with other logistic models.
One-dimensional CRM
In practice, one-dimensional CRM sometimes is used to conduct dose-combination trials [13].
Under this method, we first preselect a subset of combinations, for which the toxicity probability
order is known, and then apply the standard CRM to find the MTD. The drawback of such an
approach is that we only investigate a subset of the whole two-dimensional dose space and may
miss the true MTD. Following [13], we chose the subset of combinations as the combinations
located at anti-diagonal path: D1;1  ! D1;2  ! D2;2  ! D3;2  ! D4;2  ! D5;2  ! D5;3.
3 Simulations
We simulated 2000 independent replications of phase I trials that evaluate two agents in drug com-
binations, with five dose levels for Agent 1 and three for Agent 2, giving 15 possible combinations.
We simulated 14 scenarios to represent the possible true underlying combination toxicities (Table
1). We studied several locations of the MTD in the combination space, as well as a number of
correct combinations (or MTDs) that could shift from 0 to 3. We fixed the toxicity target at 0:3 and
used an overall sample size of 60. In this paper, we compare the performance of our method with
those of five other designs, including the BCOPULA [11] and BGUMBEL [10] methods proposed
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by Yin and Yuan, and the I2D method proposed by Wang and Ivanova [7], and with two other lo-
gistic models, LOGODDS proposed by Gasparini et al. [29] and TMML proposed by Thall [6].We
also compared the performance of this multidimensional designs with a one-dimensional CRM,
CRM anti-diag, as described previously. The design parameters of all the designs (e.g., working
model) have been calibrated via simulation before used for the comparison.
To ensure comparability, we chose a cohort size of 3 for all methods and did not use stopping
rules when comparing all the methods. The start-up phase was implemented in all simulations. Due
to ethical concerns, we started each trial at the lowest dose combination (1; 1). We selected these
features in order to employ typical trial set-ups in our simulation study. For Agent 1, we speci-
fied the marginal initial guesses of toxicities, pj , as (0:12; 0:2; 0:3; 0:4; 0:5), and for Agent 2, we
specified qk as (0:2; 0:3; 0:4). The same working models were used for BCOPULA, BGUMBEL,
LOGODDS and I2D. We set the length around the targeted interval, , at 0:1. Based on a sensitivity
analysis (data not shown), we set the probability thresholds ce and cd at 0:85 and 0:45. We recorded
5000 posterior samples of the model parameters after 2000 burn-in iterations to make inference.
After comparing the proposed design to the other designs, we also investigated the performance
of our design with the stopping rule that we introduced above. For the one-dimensional CRM, we
used the “dfcrm” R package with restrictions to avoid skipping doses. The working model was
generated using the “getprior” function with an indifference interval  = 0:05, a initial guessed
MTD at dose level 4 for a trial with 7 doses, and the same settings as for multidimensional designs
were used.
4 Results
For each scenario, we present the correct MTD selection rate, or percentages of correct selection
(PCS), in Table 2. In general, the proposed method for combination evaluation (LOGISTIC) per-
formed better than the other existing model-based designs. Indeed, except in scenarios 4 and 5, in
which the PCS were already very high (86:7% and 80:4% respectively), those in other scenarios
were either the best or not less than 2% of those of the other designs. Moreover, the PCS were
greater than 55% in all scenarios and higher than 60% in 12 scenarios out of 14.
Scenarios 1, 3 and 9 included three possible MTDs that were located on one diagonal of the
combination space; combinations (2; 3), (3; 2), (4; 1) in scenario 1, combinations (3; 3), (4; 2),
(5; 1) in scenario 3 and combinations (1; 3), (2; 2), (3; 1) in scenario 9 (Table 1). For these scenar-
ios, all model-based designs gave high PCS, whereas LOGISTIC seemed to perform better than the
other methods. In addition, for the LOGISTIC, the distribution of allocated dose levels around the
MTDs (Table 3) seemed to be spread unevenly between possible MTDs.
In scenarios 2 and 10, in which two possible MTDs were located on the same diagonal at the
lower end or at the higher end of the combination space, high PCSwere observed for the LOGISTIC
(> 75%). When the correct combination was in the lower (1; 1) extremity of the combination
space, as in scenario 4, the TMML model and then I2D method performed best (92:1% and 89:7%
respectively), but the PCS for the LOGISTIC was close to this value (86:7%). By contrast, when
the correct combination was in the higher (5; 3) extremity of the combination space, as in scenario
5, the LOGODDS model gave the highest PCS with 90:0%.
In scenarios 6, 7, 11, 12, 13 and 14, when the true MTDs were not located on the same diagonal
but randomly located in the combination space, the proposed method performed best with the PCS
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that was consistently higher than 56%. In contrast, the PCS of other methods can be as low as 30%.
For example, under scenario 6, the PCS of BCOPULA, BGUMBEL, I2D, and LOGODDS were
all lower than 47%; and under scenario 12, the PCS of TMML was only 47.9%.
Finally, when the true MTD was unique and located in the middle of the combination space,
as in scenario 8, the PCS decreased. The TMML gave the best PCS (69:7%), nevertheless the
LOGISTIC was the second most efficient design and gave good results with PCS of 56:9% for that
scenario (Table 2). The PCS of the LOGODDS was merely 12.1%.
Under our simulation setting, the one-dimensional CRM (based on an anti-diagonal subset of
combinations) yielded higher PCS than the multidimensional designs. However, this result should
not be generalized. The reason that the one-dimensional CRM performed very well is simply
because the pre-selected subset of combinations happened to include the true MTD. As the CRM
focused on only a subset of doses, it had more patients per dose to find the target doses than the
multidimensional designs, given the same total number of patients. It is easy to see that if the
true MTD(s) is (are) not contained in the pre-selected subset of ordered combinations, then the
one-dimensional CRM will perform badly and can never select the true MTD.
The mean number of DLTs observed throughout the trial in each scenario when using the LO-
GISTIC was similar to that observed when using the BCOPULA, BGUMBEL, and I2D methods
(Table 2). Over all the scenarios, the mean number of DLTs observed during the trial was 15.4,
which is lower than 18, the expected number of DLTs for 60 patients with a 0.30 toxicity probabil-
ity.
According to Table 2, the LOGISTIC tended to treat as many patients at the MTD combination
as the other methods. The lowest percentage of patients treated at the MTD combination was 24:3%
in scenario 8, and the highest was 78:0% in scenario 4. In general, the true MTD combination was
assigned to at least 1=3 of the patients, and the mean overall percentage of patients treated at the
MTD combination was 42:6%.
After employing the stopping rule for all scenarios when using the LOGISTIC, we added a
scenario in which all the dose combinations were unacceptably toxic (Table 4). The addition of the
stopping rule for unacceptable toxicity resulted in PCS that were similar to those presented above
(Table 5), except in scenario 4 in which the first dose combination, (1; 1), was the MTD. For this
scenario, the PCS decreased by 16:9%, although it was nevertheless high (69:8%). In practice,
the trial would not be completely stopped under these circumstances, but lower dose combinations
would be added to the trial. In the additional scenario 15, where all dose combinations were too
toxic, the trial was stopped in 83:7% of the cases. Therefore, the stopping rule seemed efficient.
4.1 Sensitivity analysis
We conducted a sensitivity analysis in order to study the performance of our design using different
prior distributions and parameters values. We used normal distributions centered at 0 for 0; 3
with high or low variance (from 10 to 50), and exponential or gamma distributions centered at 1 for
1; 2 with high or low variance (from 1 to 10). According to Table 5, we can see that the PCS for
all scenarios were very similar under these different prior distributions.
9
4.2 Time-to-event outcome
In practice, a longer follow-up time may be required to assess the toxicity outcome. Therefore,
the toxicity outcomes of some patients already treated in the trial may be unobserved (or censored)
when a new patient is enrolled in the trial and is ready for dose assignment. Waiting to assess
toxicity outcomes for each cohort before including a new one in the trial can greatly increase the
duration of the trial. To overcome this issue, we extended our method by modeling toxicity as
a time-to-event outcome. Following the TITE-CRM [30], we considered a weighted dose-toxicity
relationship w^F (D; 0; 1; 2; 3)where w^ is monotone and increasing with patient follow-up time
such that 0  w^  1, and the toxicity probability model F (D; 0; 1; 2; 3) = j;k is the same as
that in (1).
Let T be a (maximum) fixed time window during which patients are followed, and yi;N , Ci;N ,
and w^i;N , respectively, be the indicator of a DLT for patient i prior to the entry of the (N + 1)th
patient, the follow-up time of patient i prior to the entry of the (N + 1)th patient, and the weight
assigned to patient i prior to the entry of the (N +1)th patient. LetXi denote the time to toxicity of
the ith patient, and (ji; ki) the combination received by patient i. Before combination assignment,
the likelihood is defined as
L(0; 1; 2; 3jdata) =
NY
i=1
(w^i;Nji;ki)
yi;N (1  w^i;Nji;ki) :1 yi;N
Following Cheung and Thall [31], we chose the weights w^i;N as
w^i;N =
# fm=Xm  Ci;N ; Cm;N  Tg+ w^0i;N
# fm=Xm  T;Cm;N  Tg+ 1 ;
where m refers to patient, # fm=Xm  T;Cm;N  Tg is the number of completely followed
patients on who a toxicity was observed, and w^0i;N is the linear weight for patient i defined as
w^0i;N = Ci;N=T , that is the proportion of time patient i was followed compared to the full follow-up
time.
We simulated the time-to-toxicity outcomes using an exponential distribution such that the tox-
icity probabilities at the end of follow-up matched those given in Table 1. Using the same working
model, we chose a full follow-up time of 3 weeks, and simulated patient accrual using a Poisson
process with parameter 1, meaning that an average of one patient arrived every week.
Table 6 shows the results of the extended LOGISTIC for all 15 scenarios. We observe that the
performance of the design decreases only slightly by 2%, and the PCS for all scenarios are still very
high. This demonstrates that the LOGISTIC can be used in trials when toxicity cannot be assessed
quickly.
5 Discussion
We have proposed a statistical method for clinical trial designs that evaluate various dose com-
binations for two agents. This method seems to be capable of identifying the MTD with a high
percentage in all scenarios. Indeed, this method works for a wide variety of drug combinations.
Our aim was not to find the correct order of toxicity within the drug combination space but to
identify the right dose combination to be evaluated further in terms of efficacy. We compared our
10
method with five other model-based designs for combination drug trials. All the designs seem to be
efficient when the MTDs are located on the same diagonal in the combination space. One benefit
of our method compared with the other proposed designs is that it is also efficient when the MTDs
are not necessarily located on the same diagonal.
We have designed our method to enable the selection of only one MTD at the end of the trial.
There are various reasons why investigators may wish to select one MTD per level of Agent 2. For
this purpose, our method can be modified by selecting, for each level k of Agent 2, the combination
(jk; k) such that jk = argmax
1jJ
P (j;k 2 [   ;  + ]). In the case where it cannot be assumed
that one MTD exists per level of Agent 2, a minimum probability of being in the targeted toxicity
interval or a maximum probability of overdosing can be added in the determination of the MTD
so as not to recommend a combination in the case of an MTD not existing for this dose level of
Agent 2. Our design considers only toxicity responses, which can be improved upon by taking into
account efficacy when determining the combination to be used in subsequent phases.
When combining several agents, designs developed for single-agent dose-finding trials cannot
be applied to combination studies. For instance, the standard algorithm-based method for phase
I dose-finding clinical trials in oncology is the so-called “3+3” design, which is referred to as
“memory-less” since allocation to the next dose level for an incoming group of 3 patients depends
only upon what has happened to the total of 3 to 6 patients previously treated at the current dose
level [14, 15, 16, 17, 18]. This method was not designed for cases in which the full toxicity ordering
is unknown. Indeed, the full ordering between toxicity probabilities of each combination is not
fully known. That is why some investigators fix the dose level of one agent when they set up a
combination study. They can thereby bring the problem back to one dimension and use single-
agent designs. Another approach studied in this paper is to pre-select a subset of combinations
whose toxicity ordering is known, and then apply a single-agent design to this reduced number of
combinations. This approach performs well if the target dose combinations happen to be included
in the subset. However, in practice, due to potential interaction between combined drugs, it can
never be guaranteed that the target doses are always pre-selected into the subset of combinations
to be inverstigated. If target doses are not in the subset, the trial would completely fail to find the
target doses.
The advantage of our method is that it uses a logistic model that can be understood by a broad
panel of readers and the performance seems to outperform existing designs. We also added stopping
rules to the design in order to accommodate practical issues. The method can be efficient with
different cohort sizes. Nevertheless, estimating parameter values and the different probabilities
continues to require some advanced computational skills. To overcome this challenge, we have
developed executable files that can be used to (1) determine the next combination and the MTD
and estimate toxicity probabilities from data in actual trials, and (2) perform simulations before
setting up a combination dose-finding trial. These files are freely available upon request.
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Appendix
Gibbs sampling
Gibbs sampling was used to generate a sequence of samples from the joint probability distribution
of  = (0; 1; 2; 3). The Gibbs sampler relies on the availability of all complete conditional
distributions. We start from an arbitrary point (0) = ((0)0 ; 
(0)
1 ; 
(0)
2 ; 
(0)
3 ) in the distribution, we
sampled in turn in each of the full conditional distribution in updating them as the process goes on.
(1) Initialize (0) = ((0)0 ; 
(0)
1 ; 
(0)
2 ; 
(0)
3 )
Form from 1 toM +N
(2) Sample
 (m)0 from its full conditional distribution f(0j(m 1)1 ; (m 1)2 ; (m 1)3 ; data)
 (m)1 from its full conditional distribution f(1j(m 1)0 ; (m 1)2 ; (m 1)3 ; data)
 (m)2 from its full conditional distribution f(2j(m 1)0 ; (m 1)1 ; (m 1)3 ; data)
 (m)3 from its full conditional distribution f(3j(m 1)0 ; (m 1)1 ; (m 1)2 ; data)
) return ((M+1); : : : ; (M+N))
We chose M = 2000 number of “burn-in” iterations to be discarded before convergence.
(M) = (
(M)
0 ; 
(M)
1 ; 
(M)
2 ; 
(M)
3 ) converges in distribution to the posterior joint distribution f(0; 1; 2; 3jdata).
The following N = 5000 values retained are then considered as a sample from this distribution.
Adaptive Rejection Metropolis Sampling within Gibbs sampling
Adaptive Rejection Sampling (ARS) can not be used to sample from non log-concave distributions.
When this is the case, Gilks, Best and Tan [23] propose to replace the rejection sampling in favor of
the Hastings-Metropolis algorithm to update one parameter at a time. But to avoid high probabili-
ties of rejection, they adapted the proposal density to the shape of the full conditional density using
ARS. They added to ARS a single Hastings-Metropolis step thus creating ARMS within Gibbs
sampling. The detailed method can be found in Gilks [23].
14
Table 1: Toxicity scenarios for the two-agent combinations.
Agent 1
Agent 2 1 2 3 4 5 1 2 3 4 5
Scenario 1 Scenario 2
3 0.15 0.30 0.45 0.50 0.60 0.45 0.55 0.60 0.70 0.80
2 0.10 0.15 0.30 0.45 0.55 0.30 0.45 0.50 0.60 0.75
1 0.05 0.10 0.15 0.30 0.45 0.15 0.30 0.45 0.50 0.60
Scenario 3 Scenario 4
3 0.10 0.15 0.30 0.45 0.55 0.50 0.60 0.70 0.80 0.90
2 0.07 0.10 0.15 0.30 0.45 0.45 0.55 0.65 0.75 0.85
1 0.02 0.07 0.10 0.15 0.30 0.30 0.45 0.60 0.70 0.80
Scenario 5 Scenario 6
3 0.07 0.09 0.12 0.15 0.30 0.15 0.30 0.45 0.50 0.60
2 0.03 0.05 0.10 0.13 0.15 0.09 0.12 0.15 0.30 0.45
1 0.01 0.02 0.08 0.10 0.11 0.05 0.08 0.10 0.13 0.15
Scenario 7 Scenario 8
3 0.30 0.50 0.60 0.65 0.75 0.08 0.15 0.45 0.60 0.80
2 0.15 0.30 0.45 0.52 0.60 0.05 0.12 0.30 0.55 0.70
1 0.07 0.10 0.12 0.15 0.30 0.02 0.10 0.15 0.50 0.60
Scenario 9 Scenario 10
3 0.30 0.37 0.42 0.47 0.52 0.08 0.10 0.15 0.30 0.50
2 0.15 0.30 0.37 0.43 0.48 0.04 0.07 0.12 0.16 0.30
1 0.10 0.12 0.30 0.40 0.45 0.01 0.03 0.06 0.08 0.10
Scenario 11 Scenario 12
3 0.50 0.60 0.70 0.80 0.90 0.30 0.42 0.52 0.62 0.70
2 0.10 0.30 0.50 0.70 0.80 0.10 0.20 0.30 0.40 0.50
1 0.06 0.10 0.15 0.30 0.50 0.05 0.12 0.20 0.30 0.40
Scenario 13 Scenario 14
3 0.42 0.52 0.62 0.70 0.80 0.30 0.42 0.52 0.70 0.80
2 0.20 0.30 0.40 0.50 0.67 0.10 0.20 0.30 0.50 0.67
1 0.12 0.20 0.30 0.40 0.60 0.04 0.06 0.08 0.20 0.30
The true MTD combinations are shown in boldface.
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Table 3: Combination selection percentages of the proposed method for combination evaluation.
Agent 1
Agent 2 1 2 3 4 5 1 2 3 4 5
Scenario 1 Scenario 2
3 6.2 27.5 7.1 0.1 0.0 0.2 0.1 0.0 0.0 0.0
2 0.1 4.6 41.7 2.9 0.1 35.4 11.2 0.1 0.0 0.0
1 0.0 0.1 3.2 6.2 0.1 5.8 45.1 2.1 0.0 0.0
Scenario 3 Scenario 4
3 0.5 6.2 43.1 7.5 0.1 0.0 0.1 0.0 0.0 0.0
2 0.0 0.2 4.5 29.1 2.0 4.2 0.1 0.0 0.0 0.0
1 0.0 0.0 0.1 4.0 2.7 86.7 9.0 0.0 0.0 0.0
Scenario 5 Scenario 6
3 0.0 0.1 1.5 8.5 80.4 3.0 44.0 14.1 1.4 0.1
2 0.0 0.0 0.1 1.0 7.8 0.0 1.2 11.1 19.7 2.4
1 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.2 2.1 0.5
Scenario 7 Scenario 8
3 15.8 2.4 0.1 0.0 0.0 0.9 15.5 17.0 0.0 0.0
2 4.2 54.4 15.6 1.1 0.0 0.0 0.9 56.9 0.5 0.0
1 0.0 0.5 3.4 1.6 1.0 0.0 0.0 2.6 5.7 0.0
Scenario 9 Scenario 10
3 8.1 5.7 1.8 0.2 0.0 0.1 0.4 7.1 43.4 8.2
2 6.4 48.2 11.7 1.5 0.0 0.0 0.0 0.3 8.1 31.7
1 0.1 1.8 13.3 1.4 0.0 0.0 0.0 0.0 0.1 0.8
Scenario 11 Scenario 12
3 6.7 0.2 0.0 0.0 0.0 22.7 12.5 0.5 0.0 0.0
2 2.4 75.3 6.0 0.1 0.0 0.4 21.3 31.4 2.1 0.0
1 0.0 0.2 6.6 2.5 0.1 0.0 0.2 6.2 2.6 0.0
Scenario 13 Scenario 14
3 7.0 0.8 0.0 0.0 0.0 24.5 12.7 0.6 0.0 0.0
2 13.7 48.0 5.3 0.0 0.0 0.1 18.1 35.6 3.3 0.1
1 0.4 11.9 12.0 0.9 0.0 0.0 0.0 0.7 3.5 0.9
The percentages for the true MTD combinations are shown in boldface.
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Table 4: Additional toxicity scenario for the two-agent combinations.
Agent 1
Agent 2 1 2 3 4 5
Scenario 15
3 0.60 0.65 0.75 0.85 0.90
2 0.55 0.60 0.70 0.75 0.80
1 0.45 0.50 0.55 0.60 0.65
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Figure 2: Probability of achieving the targeted interval, P (j;k 2 [   ;  + ]) at the end of the
trial for each combination. The dashed vertical line corresponds to the highest probability, which
determines the combination selected as the MTD ((2; 3) in this example).
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